KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVS) EBT (2016 - 2025)

Historic EBT for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $3.2 billion.

  • Novartis Ag's EBT fell 203.96% to $3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $16.4 billion, marking a year-over-year increase of 1988.27%. This contributed to the annual value of $16.4 billion for FY2025, which is 1988.27% up from last year.
  • Novartis Ag's EBT amounted to $3.2 billion in Q4 2025, which was down 203.96% from $4.2 billion recorded in Q3 2025.
  • Novartis Ag's EBT's 5-year high stood at $17.0 billion during Q4 2021, with a 5-year trough of $1.6 billion in Q3 2023.
  • In the last 5 years, Novartis Ag's EBT had a median value of $3.2 billion in 2024 and averaged $3.7 billion.
  • In the last 5 years, Novartis Ag's EBT skyrocketed by 56240.72% in 2021 and then tumbled by 9074.39% in 2022.
  • Quarter analysis of 5 years shows Novartis Ag's EBT stood at $17.0 billion in 2021, then tumbled by 90.74% to $1.6 billion in 2022, then surged by 51.5% to $2.4 billion in 2023, then soared by 38.2% to $3.3 billion in 2024, then decreased by 2.04% to $3.2 billion in 2025.
  • Its EBT stands at $3.2 billion for Q4 2025, versus $4.2 billion for Q3 2025 and $4.5 billion for Q2 2025.